Effect of Esmolol on Pain Due to Rocuronium

The Effect of Esmolol on Pain Due to Rocuronium Injection Pain

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01824758

Enrollment

Registered

2013-04-05

Start date

2013-03-31

Completion date

2013-05-31

Last updated

2019-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Injection Site Irritation

Keywords

esmolol, injection pain, lidocaine, rocuronium

Brief summary

90 American society of anesthesiology (ASA) physical status I and II patients undergoing general anesthesia for elective surgery will be included in the study. Patients will be randomized into three groups. Group E will receive esmolol (1 mg/kg), Group IL lidocaine (0.5 mg/kg)and Group C placebo(NaCl 0.9%, 5 mL), followed by a 0.05 mg/kg rocuronium. After intravenous induction with propofol, adequate muscle relaxation for intubation will be received by 0.5 mg/kg rocuronium.

Detailed description

Patients will be observed after injection of rocuronium 0.05mg/kg, then immediately asked if they have pain in the arm. The response are assessed; discomfort, pain, and withdrawal of the hand are recorded and graded using a 4-point scale (none, mild, moderate, or severe). After the intubating dose of rocuronium, withdrawal reactions are scored as follows: (a) no pain response, (b)pain limited to the wrist, (c) pain limited to the elbow/shoulder, or (d) generalized pain response.

Interventions

DRUGLidocaine

Group L lidocaine (0.5 mg/kg), (rocuronium) (0.05mg/kg).

DRUGEsmolol

Group E: esmolol (1 mg/kg), (rocuronium) (0.05mg/kg)

DRUGrocuronium

0.05 mg/kg rocuronium

DRUGPlacebo

Group C: Placebo (NaCl 0.9%, 5 ml), (rocuronium) (0.05mg/kg)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* ASA physical status I and II patients * Undergoing general anesthesia for elective surgery

Exclusion criteria

* Known allergy to esmolol or lidocaine * Chronic pain * Pregnancy * Withdrawal of consent by the patient

Design outcomes

Primary

Measure	Time frame	Description
The injection pain due to rocuronium	1 month	Pain will be recorded and graded using a 4-point scale (none, mild, moderate, or severe).

Secondary

Measure	Time frame	Description
Score on pain due to injection of rocuronium	1 month	Withdrawal reactions are scored as follows: (a) no pain response, (b)pain limited to the wrist, (c) pain limited to the elbow/shoulder, or (d) generalized pain response.

Other

Measure	Time frame
To assess patient satisfaction	1 Month

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026